The complaint filed against the medical device manufacturer asserts that Insulet failed to maintain adequate oversight of its production processes, allegedly creating significant safety risks for its customers. These internal shortcomings, according to the lawsuit, rendered the company's public disclosures materially false throughout the specified class period. Shareholders who incurred financial losses during this window have until August 31, 2026, to seek appointment as a lead plaintiff.

The DJS Law Group, led by David J. Schwartz, is representing the interests of affected investors. While the firm is actively soliciting participants for the litigation, legal counsel notes that individual shareholders are not required to serve as lead plaintiffs to remain eligible for a potential recovery. The firm specializes in securities litigation and corporate governance disputes, positioning this case as part of its broader advocacy for institutional and retail investors.